Xspray Pharma AB (XSPRAY) AI Stock Analysis

• Market Cap: kr1.63B
• Dividend Yield: N/A
• Average Volume (3M): 38.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: N/A
• EPS Growth: 0.57%
• Country: SE
• Employees: 27
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -1.18
• Shares Outstanding: 37,138,493
• 10 Day Avg. Volume: 58,573
• 30 Day Avg. Volume: 38,088
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ―

Xspray Pharma AB's stock score reflects significant financial challenges, particularly the lack of revenue and increasing debt levels, which weigh heavily on the overall assessment. While technical indicators show some positive momentum, they are not strong enough to offset the financial concerns. The stock's valuation, characterized by a negative P/E ratio, underscores the company's unprofitability. To improve the stock's attractiveness, achieving revenue generation and financial sustainability will be critical.

Xspray Pharma AB Business Overview & Revenue Model

Company Description

Xspray Pharma AB (XSPRAY) is a Swedish pharmaceutical company that specializes in developing improved versions of already approved and marketed drugs. The company focuses on creating novel formulations using its proprietary HyNap technology platform, which enhances the solubility and absorption of drugs. Xspray Pharma primarily targets the oncology sector, aiming to provide competitive alternatives to existing cancer treatments with better efficacy and safety profiles.

How the Company Makes Money

Xspray Pharma makes money by developing and commercializing improved versions of existing cancer drugs. The company's revenue model is based on licensing agreements and collaborations with larger pharmaceutical companies that have the resources and distribution networks to market the drugs. By using its HyNap technology, Xspray creates formulations that offer competitive advantages over original drugs, such as enhanced bioavailability and reduced side effects, making them attractive for licensing. Xspray typically earns upfront payments, milestone payments, and royalties from these partnerships. Additionally, the company may also generate revenue through direct sales if it chooses to commercialize certain products independently.

Xspray Pharma AB Financial Statement Overview

Summary

Xspray Pharma AB faces significant financial challenges typical of early-stage biotechnology firms, such as lack of revenue generation and profitability. The strong equity position and liquidity provide some stability, but the reliance on external funding and increasing debt levels pose future risks. A focus on achieving operational efficiency and revenue generation is critical for improving financial health.

Income Statement

Xspray Pharma AB has consistently reported zero revenue over the years, indicating a lack of commercial operations or product sales. The company has been experiencing increasing losses, with net income significantly negative, which reflects ongoing financial challenges in achieving profitability. The EBIT and EBITDA margins are negative, further emphasizing the lack of operational efficiency and profitability.

Balance Sheet

The balance sheet shows a strong equity position with a high equity ratio, indicating a solid capital base. However, the company has been increasing its debt levels, which is reflected in a rising debt-to-equity ratio. Despite the challenges, a substantial portion of the assets consists of cash and short-term investments, providing some liquidity cushion.

Cash Flow

Xspray Pharma AB has been generating negative operating and free cash flows, indicating cash burn from operations and investments. The company relies heavily on financing activities for cash inflows, which could be a concern if external funding becomes less accessible. No positive growth in free cash flow has been observed, signaling potential sustainability issues.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-9.19M	-9.53M	-8.87M	-1.41M
EBITDA	-277.76M	-169.81M	-122.13M	-87.82M	-50.99M
Net Income	-285.52M	-179.67M	-130.27M	-96.70M	-52.30M
Balance Sheet
Total Assets	796.34M	765.26M	585.43M	622.90M	605.30M
Cash, Cash Equivalents and Short-Term Investments	208.24M	166.30M	120.17M	271.88M	325.60M
Total Debt	128.22M	36.81M	2.13M	3.23M	4.86M
Total Liabilities	173.25M	71.85M	29.41M	31.15M	22.72M
Stockholders Equity	623.10M	693.41M	556.02M	591.75M	582.59M
Cash Flow
Free Cash Flow	-264.51M	-257.38M	-238.47M	-147.57M	-145.00M
Operating Cash Flow	-222.37M	-203.28M	-110.18M	-51.61M	-47.79M
Investing Cash Flow	-42.14M	-65.88M	-135.34M	-105.82M	-96.83M
Financing Cash Flow	306.11M	315.59M	93.81M	103.71M	260.35M

Xspray Pharma AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 42.50
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XSPRAY, the sentiment is Neutral. The current price of 42.5 is below the 20-day moving average (MA) of 49.41, below the 50-day MA of 47.19, and above the 200-day MA of 38.42, indicating a neutral trend. The MACD of -1.05 indicates Positive momentum. The RSI at 37.60 is Neutral, neither overbought nor oversold. The STOCH value of 16.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:XSPRAY.

Xspray Pharma AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	71 Outperform	€1.13B	6.15	152.78%	―	1533.99%	―
XBRANE	58 Neutral	€436.98M	―	-47.73%	―	45.52%	93.35%
Sector *	51 Neutral	kr6.06B	7.76	-27.68%	2.23%	51.29%	15.89%
SYNACT	48 Neutral	€911.24M	―	-47.58%	―	―	57.54%
XSPRAY	47 Neutral	kr1.63B	―	-41.54%	―	―	0.57%
IRLAB.A	38 Underperform	€260.94M	―	-194.31%	―	1643.36%	50.36%
CANTA	31 Underperform	€718.49M	―	-167.55%	―	―	37.89%